This finding is consistent with previous reports that AnxA5 attenuates hepatic fibrosis and ECM deposition in high-fat diet-induced nonalcoholic steatohepatitis by downregulating α-SMA, COL III, and TGF-β expression [23]. Here, ANXA5 is linked to metabolic dysfunction-associated steatohepatitis.